ADVERTISEMENT
News
Efficacy and Safety of EDX110 for Hard-To-Heal Wounds
10/23/2024
https://clinicaltrials.gov/study/NCT06640985
A Convatec-sponsored post-market CT of 80 patients will determine the efficacy and safety of EDX110 (NO) in DFUs and VLUs resulting from venous insufficiency or diabetes with primary outcome of percentage area reduction at 12 weeks. Not yet recruiting; estimated study completion is Nov 2025. clinicaltrials.gov